Viridian Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 27.67, 231.54, 596.79, 874.18, 1155.49 ], "ebit_estimate": [ -463.26, -311.74, -49.87, 242.96, 455.04 ], "ebitda_estimate": [ -419.52, -272.38, 89.84, 770.42, 983.81 ], "net_income_estimate": [ -438.44, -301.29, 21.73, 207.79, 383.46 ], "per_share_eps_estimate": [ -3.85, -2.43, -0.2, 1.44, 2.92 ], "eps_nri_estimate": [ -3.79, -2.36, 0.44, 2.21, 3.21 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 5.91, 3.24, 2.58, null, null ], "pretax_income_estimate": [ -445.42, -291.85, -4.3, 217.58, 472.86 ], "operating_cash_flow_per_share_estimate": [ -3.44, -2.7, -1.11, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -58.75, -62.06, -38.56, null, null ], "gross_margin_estimate": [ 89.01, 88.33, 88.33, 88.5, 88.5 ], "operating_cash_flow_estimate": [ -351.61, -275.97, -113.46, null, null ], "pettm_estimate": [ 0, 0, 0, 13.67, 6.76 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "134.38", "future_per_share_eps_estimate_growth": 58.83, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 134.38, "future_ebit_estimate_growth": 47.03, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 74.23, "future_book_value_per_share_estimate_growth": -26.13, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.73, "future_operating_cash_flow_per_share_estimate_growth": 29.34 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 0.02, 10.11, 18.11, 43.06, 73.68, 95.55, 146.57, 124.53 ], "ebit_estimate": [ -120.46, -114.63, -113.93, -101.99, -72.03, -56.52, -11.79, null ], "ebitda_estimate": [ -110.94, -108.47, -92.9, -95.9, -47.54, -38.37, 31.25, null ], "net_income_estimate": [ -114.23, -108.51, -109.95, -80.21, -61.62, -47.55, -5.46, null ], "per_share_eps_estimate": [ -1.02, -0.95, -0.95, -0.69, -0.55, -0.44, -0.12, null ], "eps_nri_estimate": [ -1.03, -0.95, -0.95, -0.69, -0.55, -0.44, -0.12, -0.2 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -117.66, -110.49, -111.58, -88.11, -67.28, -52.37, -3.69, null ], "operating_cash_flow_per_share_estimate": [ -1, -0.8, -0.71, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 100, 94.5, 86.67, 87.5, 87.5, 87.5, 87.5, null ], "operating_cash_flow_estimate": [ -102.21, -81.77, -72.57, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "134.38", "future_per_share_eps_estimate_growth": 58.83, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 134.38, "future_ebit_estimate_growth": 47.03, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": 74.23, "future_book_value_per_share_estimate_growth": -26.13, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.73, "future_operating_cash_flow_per_share_estimate_growth": 29.34 }